At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 402 enrolled
Drug / intervention
H7N9c low dose with adjuvant +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I Multi-center, Observer-Blind, Randomized Dose-Ranging Study of Adjuvanted and Non-Adjuvanted Cell Culture-Derived, Inactivated A/H7N9 Monovalent Subunit Influenza Virus Vaccine (H7N9c) in Adults 18 to <65 Years
In Brief
A Phase 1 clinical trial evaluating H7N9c low dose with adjuvant, H7N9c medium dose with adjuvant, and 2 other interventions for H7N9 Influenza. Completed, enrolled 402 participants across 6 sites.
Detailed Summary
Evaluate the safety and immunogenicity of four different doses of H7N9 vaccination in adults between the ages of 18 years and 65 years.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsH7N9 Influenza
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartAug 2013
First PostedAug 2013
Primary CompletionSep 2014
TodayJul 2026
First PostedAug 26, 2013
Enrollment StartAug 1, 2013
Primary CompletionSep 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 12.8 years ago
Interventions
H7N9c low dose with adjuvantbiological
H7N9c medium dose with adjuvantbiological
H7N9c high dose with adjuvantbiological
H7N9c high dose without adjuvantbiological